MoonLake Immunotherapeutics MLTX Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's accrued expenses and other liabilities?
- MoonLake Immunotherapeutics (MLTX) reported accrued expenses and other liabilities of $21.81M in Q1 2026.
- How has MoonLake Immunotherapeutics's accrued expenses and other liabilities changed year-over-year?
- MoonLake Immunotherapeutics's accrued expenses and other liabilities increased by 106.9% year-over-year, from $10.54M to $21.81M.
- What is the long-term trend for MoonLake Immunotherapeutics's accrued expenses and other liabilities?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's accrued expenses and other liabilities has grown at a 34.3% compound annual growth rate (CAGR), from $4.52M to $14.69M.